"Atazanavir Sulfate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.
| Descriptor ID |
D000069446
|
| MeSH Number(s) |
D03.383.725.068 D12.644.456.157
|
| Concept/Terms |
Atazanavir- Atazanavir
- 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester
BMS 232632- BMS 232632
- 232632, BMS
- BMS-232632
- BMS232632
|
Below are MeSH descriptors whose meaning is more general than "Atazanavir Sulfate".
Below are MeSH descriptors whose meaning is more specific than "Atazanavir Sulfate".
This graph shows the total number of publications written about "Atazanavir Sulfate" by people in this website by year, and whether "Atazanavir Sulfate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Atazanavir Sulfate" by people in Profiles.
-
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study. Pediatr Infect Dis J. 2018 06; 37(6):e149-e156.
-
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18.
-
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS One. 2015; 10(12):e0145772.
-
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged =3 months to <6 years. J Int AIDS Soc. 2015; 18:19467.
-
Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015 May-Jun; 16(3):89-99.
-
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy. Nutrients. 2014 Nov 13; 6(11):5061-78.
-
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy. AIDS Res Hum Retroviruses. 2013 Oct; 29(10):1287-92.
-
Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005; 65(16):2309-36.
-
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.